Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | DRD3 | P35462 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12469254 | 0.95 | ALDH1A1 (0.43) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL12469400 | 0.82 | ALDH1A1 (0.44) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL15348174 | 0.77 | DRD2 (0.52) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL12468950 | 0.77 | ALDH1A1 (0.44) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL12469049 | 0.73 | ALDH1A1 (0.48) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL12469234 | 0.72 | ALDH1A1 (0.61) | ALDH1A1L3MBTL1 | |
| SCHEMBL12469411 | 0.71 | SLC6A2 (0.52) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL12469487 | 0.71 | SLC6A2 (0.52) | NPC1ALDH1A1TSHRNFKB1RAB9A | |
| SCHEMBL15348071 | 0.70 | HRH3 (0.52) | HTR2CDRD2HTR2ADRD3 | |
| SCHEMBL12469526 | 0.70 | NPSR1 (0.63) | ALDH1A1TSHRNFKB1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | EPIOMED THERAPEUTICS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012051601-A2 | HETEROARYLTHIO COMPOUNDS | EPIOMED THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289047-A1 | HETEROARYLTHIO DERIVATIVES AND ANALOGUES | NLN, HTT, ABAT | NPC1 102/4885ALDH1A1 2297/4885TSHR 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.